ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY24 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) updated its FY24 earnings guidance on Friday. The company provided EPS guidance of $4.90-5.05 for the period, compared to the consensus EPS estimate of $4.72. The company issued revenue guidance of $594-602 million, compared to the consensus revenue estimate of $590.33 million. ANI Pharmaceuticals also updated its FY 2024 guidance to 4.900-5.050 EPS.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ANIP. Raymond James lifted their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Truist Financial boosted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target on the stock. Finally, StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $77.33.

ANI Pharmaceuticals Trading Up 5.2 %

ANIP stock opened at $61.44 on Friday. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals has a twelve month low of $48.20 and a twelve month high of $70.81. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of 52.51 and a beta of 0.71. The firm’s fifty day simple moving average is $58.66 and its two-hundred day simple moving average is $61.52.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.